JP4652662B2 - Split tablet - Google Patents
Split tablet Download PDFInfo
- Publication number
- JP4652662B2 JP4652662B2 JP2002362974A JP2002362974A JP4652662B2 JP 4652662 B2 JP4652662 B2 JP 4652662B2 JP 2002362974 A JP2002362974 A JP 2002362974A JP 2002362974 A JP2002362974 A JP 2002362974A JP 4652662 B2 JP4652662 B2 JP 4652662B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- curved surface
- line
- ridge
- edge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は塩酸ベタキソロールを有効成分とする分割錠剤に関する。
【0002】
【従来技術】
塩酸ベタキソロールは、化学名(±)−1−[4−[2−(シクロプロピルメトキシ)−エチル]フェノキシ]−3−(イソプロピルアミノ)−2−プロパノール・塩酸塩で表され、三菱ウェルファーマ株式会社より商品名ケルロング(登録商標)として販売されている血管拡張性β1ブロッカーである(特開昭52−85146号公報)。現在販売されている錠剤は図1に示すような形状であり、後述の実施例で示すように分割しやすさという点では更なる改良が望まれていた。
【特許文献1】
特開昭52−85146号
【発明が解決しようとする課題】
本発明の課題は、PTPシートに包装された状態でも分割しやすく、かつ、製造工程においても、ハンドリングによる錠剤の角部の欠けなどの外観不良の発生が低減され、ツイニング(コーティング工程でコーティングフィルムが粘着して錠剤どうしがくっついてしまう現象)が防止された、塩酸ベタキソロールを有効成分とする分割錠剤を提供する点にある。
【0003】
【課題を解決するための手段】
本発明は、錠剤の形状全体に工夫を施すことで上記課題を解決できることを見出し、本発明を完成させた。
即ち、本発明の要旨は、以下のとおりである。
(1)塩酸ベタキソロールを有効成分として含む錠剤であって、該錠剤の分割を容易にする少なくとも一本の溝からなる割線を有する分割錠剤。
(2)錠剤の中心線に沿って形成された割線と、該割線により形成される2つの領域の各々に該割線を囲むように、かつ、該錠剤の縁部より内側に位置するように形成された稜線で構成された前記記載の分割錠剤。
(3)錠剤の縁部及び稜線により囲まれる部分において形成される側面部、並びに、該稜線及び中心線により囲まれる部分により形成される割線部を有する前記記載の分割錠剤。
(4)錠剤の製造工程において、該錠剤の側面部及び/または割線部における外観不良の発生が低減された前記記載の分割錠剤。
(5)錠剤の製造工程において、該錠剤の側面部及び割線部における外観不良の発生が低減された前記記載の分割錠剤。
(6)外観不良の発生が、側面部及び割線部により形成される稜線部分の欠けである前記記載の分割錠剤。
(7)側面部及び割線部により形成される稜線部分に面取りが施されている前記記載の分割錠剤。
(8)側面部において縁部と稜線とが交差する部分、及び/または、割線部において縁部と稜線とが交差する部分に、面取りが施されている前記記載の分割錠剤。
(9)側面部において縁部と稜線とが交差する部分、及び、割線部において縁部と稜線とが交差する部分に、面取りが施されている前記記載の分割錠剤。
(10)錠剤の製造工程において、錠剤どうしの付着が低減された前記記載の分割錠剤。
(11)割線部が曲面である前記記載の分割錠剤。
(12)曲面が稜線から中心線にかけて外側に向かって盛り上がる形の曲面である前記記載の分割錠剤。
(13)側面部が曲面である前記記載の分割錠剤。
(14)曲面が縁部から稜線にかけて外側に向かって盛り上がる形の曲面である前記記載の分割錠剤。
(15)コーティング錠である前記記載の分割錠剤。
【0004】
【発明の実施の形態】
以下本発明について詳細に説明する。
【0005】
本発明は、塩酸ベタキソロールを有効成分として含む錠剤であって、該錠剤の分割を容易にする少なくとも一本の溝からなる割線を有する分割錠剤である。
【0006】
本発明の分割錠剤の有効成分である塩酸ベタキソロールは、特開昭52−85146号公報に記載の方法に準じて製造可能である。
【0007】
分割錠剤は、服用量に応じて調剤時に薬剤師によって、また、服用時に患者自身によって分割される錠剤であって、個々の患者の服用量管理を最適にし、処方の際の融通性を高めるために必要とされるものである。従って、薬剤師または患者が大きな力を与えることなく容易に分割できることが必要である。また、衛生面から錠剤に直接手を触れることなく、PTPシート等の包装の上からも容易に分割できることが必要である。
【0008】
従来市販されている塩酸ベタキソロールを有効成分とする錠剤は、PTPシート等の包装の上からも分割することは困難であったが、本発明の分割錠剤においては、錠剤の分割を容易にする少なくとも一本の溝からなる割線を有するため、分割が容易である。
【0009】
また、本発明の分割錠剤においては、錠剤の中心線に沿って形成された割線と、該割線により形成される2つの領域の各々に該割線を囲むように、かつ、該錠剤の縁部より内側に位置するように形成された稜線で構成されていることが好ましい。ここで、錠剤の縁部及び稜線により囲まれる部分において形成される部分を側面部とし、該稜線及び中心線により囲まれる部分により形成される部分を割線部とすると、本発明の分割錠剤は、これらの側面部及び割線部を含む構成であることが好ましい。
【0010】
本発明の分割錠剤においては、該錠剤の製造工程において、錠剤の側面部及び割線部の欠け、詳細には側面部及び割線部により形成される稜線部分の欠けなどの外観不良の発生が低減されていること、及び/または、該錠剤の製造工程において、錠剤同士の付着が低減されていることが好ましい。
【0011】
錠剤の外観不良の発生を低減させるための一つの方法としては、錠剤の側面部及び割線部により形成される稜線部分に面取りが施されていることが挙げられる。面取りは、側面部において縁部と稜線とが交差する部分、及び/または、割線部において縁部と稜線とが交差する部分に、施されているものが好ましく、さらに、側面部において縁部と稜線とが交差する部分、及び、割線部において縁部と稜線とが交差する部分に、施されているものが特に好ましい。
【0012】
また、錠剤同士の付着を低減させるための一つの方法としては、割線部が曲面であること、詳しくは、割線部の曲面が稜線から中心線にかけて外側に向かって盛り上がる形の曲面であることが挙げられる。
【0013】
錠剤の打錠工程以降においては、ハンドリング工程や、また、素錠に対してコーティングを施したコーティング錠の場合にはコーティング工程等で、錠剤が様々な衝撃を受けやすく、角が欠けたり等の現象がおこる。このように製造工程において錠剤の外観不良が発生しやすいため、製造工程において欠けを発生しやすい部分、例えば、錠剤の側面部及び割線部に面取りを予め施しておけば、その部分の欠けの発生を低減することが可能である。
【0014】
また、コーティング錠の場合には、コーティング工程において錠剤同士が面接触する機会があれば双子錠となりコーティング不良等を発生させることとなるため、面接触が発生しない形状、例えば、割線部で錠剤同士が面接触を起こし易いのであれば、割線部を曲面にしておく、割線部の曲面が稜線から中心線にかけて外側に向かって盛り上がる形の曲面にしておくと、錠剤同士の付着を低減することが可能である。
【0015】
なお、本発明の分割錠剤は、側面部においても、曲面であること、詳細には、側面部の曲面が縁部から稜線にかけて外側に向かって盛り上がる形の曲面であることが好適な例として挙げられる。
【0016】
本発明の分割錠剤としては、主薬である塩酸ベタキソロールに、薬学上許容される適当な賦形剤、流動化剤、結合剤、滑沢剤等を含む素錠を公知の方法に準じて市販されている機器を使用して打錠して製造する。その後得られた素錠に対し、薬学上許容される適当なフィルム形成性ポリマーを含むコーティング液を用いて、慣用のコーティング方法により市販されている機器によりコーティングを行ない、コーティング錠とすることが好ましい。主薬の単位用量は1日投与量として2.5−20mgとなるように、患者の年齢、健康状態、体重、疾患の重篤度、同時に行なう治療・処置の種類や頻度、所望の効果の性質等により適宜決定することが可能である。
【0017】
【実施例】
以下、実施例により本発明をさらに詳細に説明するが、本発明はその要旨を超えない限り、以下の実施例に限定されない。なお、以下の実施例で使用した塩酸ベタキソロールは特開昭52−85146号公報に記載の方法に準じて製造したものである。
実施例1
図1及び図2に記載の素錠を製造して、各々にコーティングを施し、分割性及びコーティング工程のトラブルを比較した。図1は現在市販されている錠剤に対応する。
【0018】
各素錠は、菊水製作所製打錠機VIRGO(杵立数 18本、盤回転数 40rpm、予圧圧力 本圧の1/3、本圧圧力 1125kg)により、塩酸ベタキソロール6重量%、D-マンニトール79重量%、トウモロコシデンプン12重量%、含水二酸化ケイ素1重量%、ポリビニルアルコール1重量%、ステアリン酸マグネシウム1重量%を含む直径約6.3mm、重量約80mgの素錠として調製した。
【0019】
上記で得られた素錠にコーティング皮膜を施した。即ち、ヒドロキシプロピルメチルセルロース2910 57重量%、低置換度ヒドロキシプロピルセルロース 12重量%、マクロゴール6000 12重量%、酸化チタン 12重量%、タルク 12重量%、シリコーン樹脂 少量及び精製水からなるコーティング溶液を、HCT−30(フロイント産業社)を用い、吸気温度 80℃、排気温度43−46℃、パン回転数 15→24rpm、スプレー圧 1.5kg/cm2、スプレー速度 3.0→8.0g/minでコーティングを行なった。
【0020】
上記で得られた図1と図2の錠剤を比較した場合、図1の錠剤に比べ、図2の錠剤はその形状より、堅い平面錠で錠の割線面もしくは裏面を指などで押さえることにより簡単に分割できることから、明らかに分割性に優れていた。しかし、図2の錠剤は製造工程で錠剤の側面部及び割線部に欠けが発生し、外観不良を発生する可能性を示す摩損度試験(錠を回転ドラムに入れて回転させて欠けなどで摩損した量を測定する試験)おいて摩損度が増加した。また、図2の錠剤はコーティング中に割線面どうしが付着するツイニングが100錠中1錠の頻度で発生した。
【0021】
上記の結果より、分割性が向上し、かつ、製造工程においても、欠けの発生による外観不良を防止し、ツイニングが低減された分割錠剤を得るには、打錠工程において欠けが発生しやすい側面部及び割線部が予め面取りされていること、及び、コーティング工程において割線部どうしが付着しないように予め割線部が曲面化されていることが必要であることが示唆された。
実施例2
実施例1の結果より、図3及び図4に示す素錠を製造して、各々にコーティングを施し、分割性及びコーティング工程のトラブルを比較した。図3は、側面部のみに面取りが施されている錠剤であり、図4は、割線部と側面部との稜線全面に面取りが施されている錠剤である。
【0022】
各素錠の調製及びコーティングは実施例1と同様に行なった。
【0023】
上記で得られた各々の素錠に関して、その形状から分割性は同等であった。
【0024】
次に、実施例1と同様にして摩損度を調べたところ、図4よりも図3に示した錠剤のほうが摩損度が大きかった。
【0025】
上記で得られたコーティング錠に関して、図3及び図4に示した錠剤共にコーティング工程のツイニングはいずれの錠剤でも発生しなかった。
【0026】
【発明の効果】
本発明によれば、塩酸ベタキソロールを有効成分とする分割錠剤を得ることができる。
【図面の簡単な説明】
【図1】市販の塩酸ベタキソロールの錠剤の形状を示す図である。
【図2】本発明の分割錠剤の形状の一例を示す図である。
【図3】本発明の分割錠剤の形状の一例を示す図である。
【図4】本発明の分割錠剤の形状の一例を示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a divided tablet containing betaxolol hydrochloride as an active ingredient.
[0002]
[Prior art]
Betaxolol hydrochloride is represented by the chemical name (±) -1- [4- [2- (cyclopropylmethoxy) -ethyl] phenoxy] -3- (isopropylamino) -2-propanol hydrochloride, and Mitsubishi Pharma Corporation Further, it is a vasodilatory β1 blocker sold under the trade name Kellong (registered trademark) (Japanese Patent Laid-Open No. 52-85146). The tablet currently on the market has a shape as shown in FIG. 1, and further improvements have been desired in terms of ease of division as shown in the examples described later.
[Patent Document 1]
JP-A-52-85146 [Problems to be solved by the invention]
The problem of the present invention is that it is easy to divide even when packaged in a PTP sheet, and the occurrence of poor appearance such as chipping of the corners of the tablet due to handling is reduced even in the manufacturing process. Is a split tablet containing betaxolol hydrochloride as an active ingredient, in which the phenomenon that the tablets stick to each other is prevented.
[0003]
[Means for Solving the Problems]
This invention discovered that the said subject could be solved by devising the whole shape of a tablet, and completed this invention.
That is, the gist of the present invention is as follows.
(1) A tablet comprising betaxolol hydrochloride as an active ingredient and having a secant line comprising at least one groove for facilitating the tablet division.
(2) The dividing line formed along the center line of the tablet and the two areas formed by the dividing line so as to surround the dividing line and to be located inside the edge of the tablet The divided tablet as described above, which is composed of a ridgeline formed.
(3) The divided tablet according to the above, having a side surface portion formed in a portion surrounded by the edge portion and the ridge line of the tablet, and a secant portion formed by a portion surrounded by the ridge line and the center line.
(4) In the tablet production process, the divided tablet according to the above, wherein occurrence of poor appearance in the side surface portion and / or secant portion of the tablet is reduced.
(5) In the tablet manufacturing process, the divided tablet according to the above, wherein appearance defects are reduced in the side surface and the secant part of the tablet.
(6) The divided tablet according to the above, wherein the occurrence of poor appearance is a lack of a ridge portion formed by the side surface portion and the dividing line portion.
(7) The divided tablet according to the above, wherein the ridge line portion formed by the side surface portion and the dividing line portion is chamfered.
(8) The divided tablet according to the above, wherein chamfering is applied to a portion where the edge portion and the ridge line intersect in the side surface portion and / or a portion where the edge portion and the ridge line intersect in the dividing line portion.
(9) The divided tablet according to the above, wherein chamfering is applied to a portion where the edge portion and the ridge line intersect in the side surface portion and a portion where the edge portion and the ridge line intersect in the dividing line portion.
(10) The divided tablet as described above, wherein adhesion between tablets is reduced in the tablet production process.
(11) The divided tablet according to the above, wherein the secant part is a curved surface.
(12) The divided tablet as described above, wherein the curved surface is a curved surface bulging outward from the ridgeline to the centerline.
(13) The divided tablet according to the above, wherein the side surface is a curved surface.
(14) The divided tablet as described above, wherein the curved surface is a curved surface that bulges outward from the edge to the ridgeline.
(15) The divided tablet as described above, which is a coated tablet.
[0004]
DETAILED DESCRIPTION OF THE INVENTION
The present invention will be described in detail below.
[0005]
The present invention is a tablet containing betaxolol hydrochloride as an active ingredient and having a secant line composed of at least one groove that facilitates the division of the tablet.
[0006]
Betaxolol hydrochloride, which is an active ingredient of the divided tablet of the present invention, can be produced according to the method described in JP-A-52-85146.
[0007]
Divided tablets are tablets that are divided by the pharmacist at the time of dispensing according to the dose and by the patient himself at the time of taking to optimize individual patient dose management and increase flexibility in prescribing It is what is needed. Therefore, it is necessary that the pharmacist or patient can be easily divided without giving a great force. In addition, it is necessary that the tablet can be easily divided from the top of the packaging such as a PTP sheet without directly touching the tablet from the hygiene aspect.
[0008]
Conventionally commercially available tablets containing betaxolol hydrochloride as an active ingredient have been difficult to divide even from the top of packaging such as PTP sheets. However, in the divided tablets of the present invention, at least the tablet can be easily divided. Since it has a secant consisting of a single groove, it is easy to divide.
[0009]
In the divided tablet of the present invention, the dividing line formed along the center line of the tablet and the two regions formed by the dividing line are surrounded by the dividing line and from the edge of the tablet. It is preferable that the ridge line is formed so as to be located inside. Here, when the part formed in the part surrounded by the edge and the ridge line of the tablet is a side part, and the part formed by the part surrounded by the ridge line and the center line is a dividing line part, the divided tablet of the present invention is It is preferable that it is the structure containing these side parts and a parting part.
[0010]
In the divided tablet of the present invention, in the tablet production process, occurrence of poor appearance such as chipping of the side surface portion and the dividing line portion of the tablet, specifically, chipping of the ridge line portion formed by the side surface portion and the dividing line portion is reduced. It is preferable that adhesion between the tablets is reduced in the manufacturing process of the tablets.
[0011]
One method for reducing the occurrence of poor appearance of the tablet is that chamfering is applied to the ridge line portion formed by the side surface portion and the dividing line portion of the tablet. The chamfering is preferably applied to a portion where the edge and the ridge line intersect in the side surface portion and / or a portion where the edge and the ridge line intersect in the dividing line portion, and further, the chamfering is performed with the edge portion in the side surface portion. What is applied to the portion where the ridge line intersects and the portion where the edge portion and the ridge line intersect in the dividing line portion is particularly preferable.
[0012]
In addition, as one method for reducing the adhesion between tablets, the secant part is a curved surface. Specifically, the curved surface of the secant part is a curved surface that rises outward from the ridge line to the center line. Can be mentioned.
[0013]
After the tableting process, the tablet is easily subjected to various impacts, such as the handling process and, in the case of a coated tablet with a coating applied to the uncoated tablet, the tablet may be subject to various impacts, A phenomenon occurs. In this way, since the appearance of the tablet is likely to be poor in the manufacturing process, if the chamfer is applied in advance to the part that is likely to be chipped in the manufacturing process, for example, the side part and the score line part of the tablet, the chipping of the part is generated. Can be reduced.
[0014]
In the case of coated tablets, if there is an opportunity for tablets to come into surface contact with each other in the coating process, it will be a twin tablet and will cause poor coating, etc. If it is easy to cause surface contact, if the secant part is curved, and the curved surface of the secant part rises outward from the ridge line to the center line, adhesion between tablets can be reduced. Is possible.
[0015]
It should be noted that the divided tablet of the present invention is also a curved surface in the side surface portion, and more specifically, it is preferable that the curved surface of the side surface portion is a curved surface that bulges outward from the edge portion to the ridge line. It is done.
[0016]
As the split tablet of the present invention, uncoated tablets containing a suitable pharmaceutically acceptable excipient, a fluidizing agent, a binder, a lubricant and the like in betaxolol hydrochloride as the main drug are commercially available according to known methods. Tablets are manufactured using the equipment that is used. The resulting uncoated tablet is preferably coated with a commercially available device by a conventional coating method using a coating solution containing a suitable pharmaceutically acceptable film-forming polymer, and is preferably used as a coated tablet. . The unit dose of the active ingredient is 2.5-20 mg as the daily dose, so that the patient's age, health, weight, severity of the disease, the type and frequency of the treatment / treatment to be performed simultaneously, and the nature of the desired effect It is possible to determine as appropriate.
[0017]
【Example】
EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to a following example, unless the summary is exceeded. In addition, the betaxolol hydrochloride used in the following examples was produced according to the method described in JP-A-52-85146.
Example 1
The uncoated tablets shown in FIG. 1 and FIG. 2 were produced, each was coated, and the splitting property and trouble in the coating process were compared. FIG. 1 corresponds to a tablet currently on the market.
[0018]
Each uncoated tablet is 6% by weight of betaxolol hydrochloride, D-mannitol 79 using a tableting machine VIRGO (Kikusui Seisakusho, 18 standing, 40 rpm, preload pressure 1/3 main pressure, 1125 kg main pressure). It was prepared as an uncoated tablet having a diameter of about 6.3 mm and a weight of about 80 mg containing 12% by weight, corn starch 12% by weight, hydrous silicon dioxide 1% by weight, polyvinyl alcohol 1% by weight, and magnesium stearate 1% by weight.
[0019]
The uncoated tablet obtained above was coated with a coating film. That is, a coating solution comprising 57% by weight of hydroxypropyl methylcellulose 2910, 12% by weight of low-substituted hydroxypropyl cellulose, 12% by weight of macrogol 6000, 12% by weight of titanium oxide, 12% by weight of talc, a small amount of silicone resin and purified water, Using HCT-30 (Freund Sangyo Co., Ltd.), intake temperature 80 ° C, exhaust temperature 43-46 ° C, pan rotation speed 15 → 24rpm, spray pressure 1.5kg / cm2, spray speed 3.0 → 8.0g / min Coating was performed.
[0020]
When the tablet of FIG. 1 and FIG. 2 obtained above is compared, the tablet of FIG. 2 is harder than its shape, and the tablet of FIG. Since it can be divided easily, it was clearly superior in dividing property. However, the tablet shown in FIG. 2 has a friability test that shows the possibility of chipping at the side and score lines of the tablet during the manufacturing process, resulting in poor appearance. The friability increased in the test of measuring the amount of Further, in the tablet of FIG. 2, the twining in which the secant surfaces adhere to each other during coating occurred at a frequency of 1 tablet per 100 tablets.
[0021]
From the above results, in order to obtain a divided tablet with improved splitting properties and preventing appearance defects due to chipping in the manufacturing process and reduced twinning, the chipping process is likely to be chipped. It has been suggested that it is necessary to chamfer the part and the parting part in advance, and that the parting part should be curved in advance so that the parting parts do not adhere to each other in the coating process.
Example 2
From the results of Example 1, the uncoated tablets shown in FIGS. 3 and 4 were produced, and each was coated, and the splitting property and troubles in the coating process were compared. FIG. 3 shows a tablet in which only the side surface portion is chamfered, and FIG. 4 shows a tablet in which the entire ridge line between the dividing line portion and the side surface portion is chamfered.
[0022]
Each uncoated tablet was prepared and coated in the same manner as in Example 1.
[0023]
With respect to each of the uncoated tablets obtained above, the splitting ability was equivalent due to its shape.
[0024]
Next, when the friability was examined in the same manner as in Example 1, the friability of the tablet shown in FIG. 3 was greater than that of FIG.
[0025]
Regarding the coated tablets obtained above, the twisting in the coating process did not occur in any of the tablets shown in FIGS. 3 and 4.
[0026]
【The invention's effect】
According to the present invention, a divided tablet containing betaxolol hydrochloride as an active ingredient can be obtained.
[Brief description of the drawings]
BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a diagram showing the shape of a commercially available betaxolol hydrochloride tablet.
FIG. 2 is a diagram showing an example of the shape of a divided tablet of the present invention.
FIG. 3 is a diagram showing an example of the shape of a divided tablet of the present invention.
FIG. 4 is a diagram showing an example of the shape of a divided tablet according to the present invention.
Claims (3)
a)錠剤の中心線に沿って形成され、錠剤の分割を容易にする少なくとも一本の溝からなる割線と、
b)該割線により形成される2つの領域の各々に該割線を囲むように、かつ、該錠剤の縁部と中心線のほぼ中央に位置するように形成された稜線を有し、
c)上記割線を形成する溝の頂角が100°であり、
d)錠剤の縁部及び稜線により囲まれる部分において形成される側面部が曲面であって、該曲面が縁部から稜線にかけて外側に向かって盛り上がる形の曲面であり、
e)稜線及び中心線により囲まれる部分により形成される割線部が曲面であって、該曲面が稜線から中心部にかけて外側に向かって盛り上がる形の曲面であり、
f)該側面部及び割線部により形成される稜線部分全面に面取りが施されており、
g)側面部において縁部と稜線とが交差する部分、及び、割線部において縁部と稜線とが
交差する部分に面取りが施されている、
易分割錠剤。 Look including a betaxolol hydrochloride as an active ingredient, a tablet comprising coated by coating the tablet,
a) is formed along the center line of the tablet, and the dividing line consisting of at least one groove which facilitates division of the tablet,
b) to each of the two regions formed by the dividing line so as to surround the該割line, and has a ridge that is formed so as to be located substantially at the center of the edge and the center line of the tablet,
c) The apex angle of the groove forming the secant is 100 °,
d) The side surface formed in the part surrounded by the edge and the ridgeline of the tablet is a curved surface, and the curved surface is a curved surface that bulges outward from the edge to the ridgeline ,
e) The secant part formed by the part surrounded by the ridge line and the center line is a curved surface, and the curved surface is a curved surface that bulges outward from the ridge line to the center part;
f) chamfered ridge portion entirely formed by the side portions and the dividing line portion is subjected,
edge and ridge and a portion intersecting at g) side surface portion, and, and the edge and the ridge has a surface up is performed at the intersection in the secant section,
Easy split tablet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002362974A JP4652662B2 (en) | 2002-12-13 | 2002-12-13 | Split tablet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002362974A JP4652662B2 (en) | 2002-12-13 | 2002-12-13 | Split tablet |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004189703A JP2004189703A (en) | 2004-07-08 |
JP4652662B2 true JP4652662B2 (en) | 2011-03-16 |
Family
ID=32761265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002362974A Expired - Lifetime JP4652662B2 (en) | 2002-12-13 | 2002-12-13 | Split tablet |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4652662B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006280656B2 (en) * | 2005-08-18 | 2012-09-20 | Teijin Limited | Preparation with accurate dose-dividing function |
JP6482933B2 (en) * | 2015-04-13 | 2019-03-13 | 株式会社京都製作所 | Alignment device and alignment / conveyance device |
JP6967833B2 (en) * | 2015-11-30 | 2021-11-17 | 大原薬品工業株式会社 | How to provide double-sided printing information for compound locks using a pharmaceutical packaging box |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051207A1 (en) * | 1998-04-03 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Split tablet and press-through pack |
-
2002
- 2002-12-13 JP JP2002362974A patent/JP4652662B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051207A1 (en) * | 1998-04-03 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Split tablet and press-through pack |
Also Published As
Publication number | Publication date |
---|---|
JP2004189703A (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2329812B1 (en) | Film-coated scored tablet | |
JP2014076998A (en) | Pharmaceutical compositions | |
KR100322340B1 (en) | Oral cholesterol lowering agents | |
KR20180004839A (en) | Titration of tapentadol | |
SK105698A3 (en) | Method of treatment and pharmaceutical composion | |
US20100255082A1 (en) | Functionally Coated Breakable Tablets | |
US20200368216A1 (en) | Treatment of sunburn using analgesics and antihistamines | |
JP4652662B2 (en) | Split tablet | |
AU2003287488B8 (en) | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally | |
EP2467136B1 (en) | 4-methylpyrazole formulations | |
AU2005231479C1 (en) | (R,R)-formoterol in combination with other pharmacological agents | |
JP3015677B2 (en) | Divided tablets with film coating | |
MXPA05006203A (en) | Stable topiramate formulations. | |
EP1326586B1 (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
JP2022011000A (en) | Azilsartan preparation | |
JP5049517B2 (en) | Split tablet | |
KR20010052895A (en) | Method of Treatment | |
US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
US9011904B2 (en) | Self-breaking tablets | |
JP5320759B2 (en) | Secant tablet | |
EP4479028A1 (en) | Trimodal, precision-timed release tablet | |
JP5692270B2 (en) | Secant tablet | |
JP2005500367A (en) | Pramipexole as an anticonvulsant | |
AU2011236040A1 (en) | (R,R)-Formoterol in combination with other pharmacological agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051213 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070427 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20071102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090924 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100915 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101019 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4652662 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131224 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
EXPY | Cancellation because of completion of term |